Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia

Purpose To compare clinical and microbiological efficacy of colistin and colistin/sulbactam for the treatment of multidrug-resistant (MDR) Acinetobacter baumannii VAP in intensive care units (ICUs). Patients and methods In this retrospective analysis, patients (>16 years-old) who received IV coli...

Full description

Saved in:
Bibliographic Details
Published in:Infection 2014-02, Vol.42 (1), p.37-42
Main Authors: Kalin, G., Alp, E., Akin, A., Coskun, R., Doganay, M.
Format: Article
Language:English
Subjects:
Acinetobacter baumannii - drug effects
Acinetobacter baumannii - isolation & purification
Acinetobacter Infections - drug therapy
Acinetobacter Infections - microbiology
Administration, Intravenous
Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents - therapeutic use
Clinical and Epidemiological Study
Colistin - therapeutic use
Drug Resistance, Multiple, Bacterial
Drug Therapy - methods
Family Medicine
Female
General Practice
Humans
Infectious Diseases
Intensive Care Units
Internal Medicine
Male
Medicine
Medicine & Public Health
Middle Aged
Pneumonia, Ventilator-Associated - drug therapy
Pneumonia, Ventilator-Associated - microbiology
Retrospective Studies
Sulbactam - therapeutic use
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To compare clinical and microbiological efficacy of colistin and colistin/sulbactam for the treatment of multidrug-resistant (MDR) Acinetobacter baumannii VAP in intensive care units (ICUs). Patients and methods In this retrospective analysis, patients (>16 years-old) who received IV colistin or colistin/sulbactam for the treatment of MDR A. baumannii VAP were evaluated. The clinical and microbiological responses to therapies were assessed on the fifth day and at the end of the therapy. Results During the study period, 89 patients were enrolled into the study. Fifty-two (58.4 %) patients received colistin and 37 (41.6 %) patients received colistin/sulbactam therapy. The median APACHE II score was higher and diabetes mellitus was more common in the colistin/sulbactam group ( p  
ISSN:0300-8126
1439-0973
DOI:10.1007/s15010-013-0495-y